ESR1 and breast carcinoma: The selective estrogen receptor modulators (SERMs) are effective for hormone receptor‐positive breast cancers; however, high cost and side effects are often reported by breast cancer patients (Foulkes, Smith, & Reis‐Filho, 2010).